OraSure Technologies (NASDAQ:OSUR) Director Steven Kyle Boyd Purchases 25,000 Shares of Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) Director Steven Kyle Boyd acquired 25,000 shares of OraSure Technologies stock in a transaction dated Tuesday, May 12th. The shares were acquired at an average price of $2.98 per share, with a total value of $74,500.00. Following the completion of the acquisition, the director directly owned 63,462 shares of the company’s stock, valued at approximately $189,116.76. The trade was a 65.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Steven Kyle Boyd also recently made the following trade(s):

• On Thursday, May 14th, Steven Kyle Boyd bought 25,000 shares of OraSure Technologies stock. The shares were acquired at an average cost of $2.99 per share, with a total value of $74,750.00.

OraSure Technologies Price Performance

OSUR opened at $2.95 on Friday. OraSure Technologies, Inc. has a fifty-two week low of $2.08 and a fifty-two week high of $3.82. The firm has a market capitalization of $203.11 million, a PE ratio of -2.84 and a beta of 0.89. The company’s 50-day moving average is $3.06 and its 200 day moving average is $2.76.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02). The business had revenue of $26.76 million during the quarter, compared to the consensus estimate of $26.44 million. OraSure Technologies had a negative net margin of 66.42% and a negative return on equity of 18.57%.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, May 7th. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average target price of $3.00.

Hedge Funds Weigh In On OraSure Technologies

Institutional investors have recently modified their holdings of the business. Amundi purchased a new stake in shares of OraSure Technologies during the first quarter valued at approximately $47,000. AQR Capital Management LLC grew its stake in OraSure Technologies by 48.3% in the 1st quarter. AQR Capital Management LLC now owns 1,041,875 shares of the medical instruments supplier’s stock valued at $3,511,000 after purchasing an additional 339,493 shares during the period. NewEdge Advisors LLC grew its stake in OraSure Technologies by 32,595.9% in the 1st quarter. NewEdge Advisors LLC now owns 47,736 shares of the medical instruments supplier’s stock valued at $161,000 after purchasing an additional 47,590 shares during the period. Empowered Funds LLC increased its position in shares of OraSure Technologies by 7.2% during the 1st quarter. Empowered Funds LLC now owns 405,216 shares of the medical instruments supplier’s stock valued at $1,366,000 after purchasing an additional 27,310 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its stake in shares of OraSure Technologies by 32.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 8,133 shares during the period. 93.50% of the stock is owned by institutional investors.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.